FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) — Phathom Prescribed drugs, Inc. (Nasdaq: PHAT), a biopharmaceutical firm centered on growing and commercializing novel therapies for gastrointestinal (GI) illnesses, at this time introduced that the corporate will current information from a number of investigational research for its first-in-class remedy VOQUEZNA ® (vonoprazan) tablets on the American Faculty of Gastroenterology (ACG) 2024 Annual Scientific Assembly, being held October 25-30 in Philadelphia, PA. VOQUEZNA is accredited for the reduction of heartburn related to Non-Erosive Gastroesophageal Reflux Illness (Non-Erosive GERD), for the remedy of all severities of Erosive Esophagitis, generally known as Erosive GERD, and reduction of associated heartburn, and together with antibiotics for the eradication of Helicobacter pylori (H. pylori) an infection.1 VOQUEZNA is the primary and solely U.S. Meals and Drug Administration (FDA)-approved potassium-competitive acid blocker (PCAB).2
Evaluating On-Demand VOQUEZNA Therapy from the PHALCON-NERD-201 Trial3
In an oral presentation being offered Monday, October 28 at ACG, Ronnie Fass, M.D., director of the Division of Gastroenterology and Hepatology and medical director of the Digestive Well being Middle at MetroHealth in Cleveland, Ohio, and lead investigator of the PHALCON-NERD-201 trial, will present outcomes from a post-hoc evaluation of the Part 2 research. This analysis, acknowledged with the ACG Excellent Analysis Award within the ˜Esophagus’ class, evaluated the efficacy of As Wanted (On-Demand) dosing of VOQUEZNA, in comparison with placebo, for reduction of episodic heartburn in individuals with Non-Erosive GERD following a 4-week VOQUEZNA every day dosing run-in interval. As beforehand reported, the first evaluation of the research demonstrated that each one three VOQUEZNA doses examined (10 mg, 20 mg and 40 mg) had increased percentages of heartburn fully relieved inside three hours of dosing and sustained for twenty-four hours, with important variations reported as early as one hour. Use of As Wanted dosing on this inhabitants is investigational as VOQUEZNA has been neither evaluated nor accredited by the FDA as an As Wanted remedy for Non-Erosive GERD.
To grasp the sensible software of As Wanted dosing for VOQUEZNA, the brand new evaluation examined every day heartburn symptom burden at baseline, throughout every day VOQUEZNA remedy, and upon switching to As Wanted remedy after reaching symptom management throughout the run-in interval. It additionally additional evaluated the speed of symptom enchancment upon treating new onset heartburn episodes throughout the As Wanted dosing interval.3
As a healthcare supplier, the idea of a novel As Wanted dosing choice for Non-Erosive GERD is extremely compelling. I’m happy that ACG has acknowledged this information as a recipient of the ACG Excellent Analysis Award, additional reinforcing its significance to the GI group, mentioned Ronnie Fass, M.D. The low frequency of heartburn after discontinuing every day VOQUEZNA remedy, coupled with the speedy onset of enchancment following As Wanted dosing, means that transitioning from every day dosing to As Wanted remedy is a viable choice for sufferers who beforehand reply nicely to every day remedy of VOQUEZNA. These promising outcomes warrant additional investigation in a bigger and prolonged As Wanted research interval.
The double-blind, placebo-controlled PHALCON-NERD Part 2 research randomized 207 sufferers who have been eligible for On-Demand (As Wanted) remedy following a 4-week every day dosing run-in interval wherein sufferers obtained VOQUEZNA 20 mg once-daily. Sufferers with out heartburn within the final seven days of the run-in interval have been evenly randomized to obtain 10 mg, 20 mg or 40 mg of VOQUEZNA, or placebo, for six weeks. Outcomes of the research have been revealed in Alimentary Pharmacology & Therapeutics in September 2023.4
Outcomes:3
- Sufferers eligible for the On-Demand interval (n=207) have been extremely symptomatic with a reported imply of 16.1% [95% CI: (13.5%, 18.7%)] heartburn-free days throughout screening. Heartburn-free days elevated throughout the run-in interval to a imply of 82.9% [95% CI: (80.4%, 85.4%)] and remained nicely above pre-treatment ranges (means 71% to 75%) all through the six-week On-Demand interval.
- The distinction within the enchancment of handled heartburn episodes between the energetic and placebo teams turned evident inside the first hour of dosing (10 mg [75.5%, p<0.0001], 20 mg [69.1%, p = 0.0010], 40 mg [75.5%, p<0.0001], placebo [57.0%]).
- Over 90% of heartburn episodes handled with VOQUEZNA improved inside two hours.
Non-Erosive GERD is the most important class of GERD and is characterised by reflux-related signs within the absence of esophageal mucosal erosions. An estimated 45 million U.S. adults reside with Non-Erosive GERD, and roughly 15 million are handled with a prescription drugs yearly. Regardless of longstanding remedy choices, many sufferers proceed to undergo from heartburn signs. As Wanted dosing is a singular and differentiated dosing routine for which proton pump inhibitors (PPIs), a mainstay of GERD remedy, aren’t accredited in the united states5
In July 2024, VOQUEZNA was accredited by the FDA as a every day dosing remedy for the reduction of heartburn related to Non-Erosive GERD in adults.1
Nocturnal GERD Signs in Non-Erosive GERD6
In a poster presentation on Monday, October 28 at ACG, which has obtained ACG’s Presidential Poster Award, Dr. Catiele Antunes, M.D., Yale New Haven Hospital, will current information wanting on the frequent, but occasionally evaluated, nocturnal signs amongst sufferers with Non-Erosive GERD. The research included an exploratory evaluation of a validated patient-reported outcomes scale, the Nocturnal Gastro-esophageal reflux illness Symptom Severity and Impression Questionnaire (N-GSSIQ), to find out the severity, morning influence, and concern about nocturnal GERD.
We’re more than happy to proceed so as to add to the physique of scientific analysis evaluating the potential advantages of VOQUEZNA for GERD sufferers, mentioned Eckhard Leifke, M.D., Chief Medical Officer at Phathom. In our research, sufferers who skilled nocturnal GERD signs previous to VOQUEZNA remedy discovered efficient and significant reduction with every day dosing, reinforcing its potent and sturdy acid suppression profile in serving to to deal with each daytime and nighttime heartburn. Whereas these findings are exploratory, they present promise for the numerous people affected by nocturnal GERD signs.
Outcomes:6
- Amongst 772 topics, the imply proportion of heartburn-free nights throughout the screening interval was 29.6%, 25.8% and 31.1%, for sufferers randomized to placebo, VOQUEZNA 10 mg and 20 mg, respectively.
- After 4 weeks, the least-square (LS) imply proportion of heartburn-free nights was considerably higher with 59.9% for VOQUEZNA 10 mg (LS imply distinction=16.5%, p<0.0001 vs. placebo), and 56.4% for VOQUEZNA 20 mg (LS imply distinction=13.1%, p<0.0001 vs. placebo), in comparison with 43.3% for placebo. The median proportion of heartburn-free nights was 70.4% for VOQUEZNA 10 mg and 71.0% for VOQUEZNA 20 mg, in comparison with 45.5% for placebo.
- N-GSSIQ scores confirmed important enchancment with VOQUEZNA in comparison with placebo in whole rating (LS imply distinction vs. placebo of -2.9 and -1.8 for VOQUEZNA 10 mg and 20 mg, respectively; p<0.005 for each comparisons), nocturnal symptom severity (LS imply distinction vs. placebo of -5.4 and -3.5 for VOQUEZNA 10 mg and 20 mg; p<0.001 for each comparisons), and concern about nocturnal GERD (LS imply distinction vs. placebo of -2.0 for each VOQUEZNA 10 mg and 20 mg; p<0.0001).
Along with these information displays, Phathom will sponsor a product theater highlighting VOQUEZNA as an accredited remedy for GERD and also will have a presence on the exhibit ground at sales space #757 all through the convention.
Following the conclusion of ACG 2024, the abstracts will probably be posted to the publications and scientific part of the Phathom firm web site.
VOQUEZNA is marketed completely by Phathom Prescribed drugs, Inc. and is at present accessible through prescription. Please go to voqueznapro.com to study extra about VOQUEZNA.
About Non-Erosive Gastroesophageal Reflux Illness
Non-Erosive GERD is the most important class of GERD and is characterised by reflux-related signs within the absence of esophageal mucosal erosions. There are over 65 million U.S. sufferers residing with GERD, and it’s estimated that roughly 70% of this inhabitants have Non-Erosive GERD. Signs of Non-Erosive GERD could influence total high quality of life and may embody episodic heartburn, particularly at night time, regurgitation, issues swallowing, and chest ache.7,8
About VOQUEZNA ®
VOQUEZNA ® (vonoprazan) tablets comprise vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion within the abdomen. VOQUEZNA is accredited within the U.S. for the remedy of adults with Erosive Esophagitis, often known as Erosive GERD, the reduction of heartburn related to Erosive GERD, the reduction of heartburn related to Non-Erosive GERD, and for the remedy of H. pylori an infection together with both amoxicillin or amoxicillin and clarithromycin. Phathom in-licensed the U.S. rights to vonoprazan from Takeda, which markets the product in Japan and quite a few different nations in Asia and Latin America.
About Phathom Prescribed drugs, Inc.
Phathom Prescribed drugs is a biopharmaceutical firm centered on the event and commercialization of novel therapies for gastrointestinal illnesses. Phathom has in-licensed the unique rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that’s at present marketed in the US as VOQUEZNA ® (vonoprazan) tablets for the remedy of heartburn related to Non-Erosive GERD in adults, the therapeutic and upkeep of therapeutic of Erosive GERD in adults and related heartburn, along with VOQUEZNA ® TRIPLE PAK ® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA ® DUAL PAK ® (vonoprazan tablets, amoxicillin capsules) for the remedy of H. pylori an infection in adults. For extra details about Phathom, go to the corporate’s web site at www.phathompharma.com and observe on LinkedIn and X.
INDICATIONS AND USAGE
VOQUEZNA ® (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated in adults:
- for the therapeutic of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Illness or Erosive GERD) and reduction of heartburn related to Erosive GERD.
- to keep up therapeutic of all grades of Erosive GERD and reduction of heartburn related to Erosive GERD.
- for the reduction of heartburn related to Non-Erosive GERD.
- together with amoxicillin and clarithromycin for the remedy of Helicobacter pylori (H. pylori) an infection.
- together with amoxicillin for the remedy of H. pylori an infection.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
VOQUEZNA is contraindicated in sufferers with a identified hypersensitivity to vonoprazan or any part of VOQUEZNA, or in sufferers receiving rilpivirine-containing merchandise.
For details about contraindications of antibacterial brokers (clarithromycin and amoxicillin) indicated together with VOQUEZNA, check with the Contraindications part of the corresponding prescribing info.
WARNINGS AND PRECAUTIONS
Presence of Gastric Malignancy: In adults, symptomatic response to remedy with VOQUEZNA doesn’t preclude the presence of gastric malignancy. Take into account further follow-up and diagnostic testing in sufferers who’ve a suboptimal response or an early symptomatic relapse after finishing remedy with VOQUEZNA. In older sufferers, additionally take into account endoscopy.
Acute Tubulointerstitial Nephritis: Acute tubulointerstitial nephritis (TIN) has been reported with VOQUEZNA. If suspected, discontinue VOQUEZNA and consider sufferers with suspected acute TIN.
Clostridioides difficile-Related Diarrhea: Printed observational research recommend that proton pump inhibitors (PPIs) could also be related to an elevated danger of Clostridioides difficile-associated diarrhea (CDAD), particularly in hospitalized sufferers. VOQUEZNA may improve the danger of CDAD. Take into account CDAD in sufferers with diarrhea that doesn’t enhance. Use the shortest length of VOQUEZNA acceptable to the situation being handled.
CDAD has been reported with use of practically all antibacterial brokers. For extra info particular to antibacterial brokers (clarithromycin and amoxicillin) indicated to be used together with VOQUEZNA, check with Warnings and Precautions part of the corresponding prescribing info.
Bone Fracture: A number of revealed observational research recommend that PPI remedy could also be related to an elevated danger for osteoporosis-related fractures of the hip, wrist, or backbone, particularly in sufferers receiving excessive dose (a number of every day doses) and long-term remedy (a yr or longer). Bone fracture, together with osteoporosis-related fracture, has additionally been reported with vonoprazan. Use the shortest length of VOQUEZNA acceptable to the situation being handled. Sufferers in danger for osteoporosis-related fractures ought to be managed in line with the established remedy pointers.
Extreme Cutaneous Hostile Reactions (SCAR): Extreme cutaneous antagonistic reactions, together with Stevens-Johnson syndrome (SJS) and poisonous epidermal necrolysis (TEN) have been reported with VOQUEZNA. Discontinue VOQUEZNA on the first indicators or signs of SCAR or different indicators of hypersensitivity and take into account additional analysis.
Vitamin B12 (Cobalamin) Deficiency: Lengthy-term use of acid-suppressing medication can result in malabsorption of Vitamin B12 brought on by hypo- or achlorhydria. Vitamin B12 deficiency has been reported postmarketing with vonoprazan. If scientific signs in step with vitamin B12 deficiency are noticed in sufferers handled with VOQUEZNA, take into account additional workup.
Hypomagnesemia and Mineral Metabolism: Hypomagnesemia has been reported postmarketing with vonoprazan. Hypomagnesemia could result in hypocalcemia and/or hypokalemia and should exacerbate underlying hypocalcemia in at-risk sufferers.
Take into account monitoring magnesium ranges previous to initiation of VOQUEZNA and periodically in sufferers anticipated to be on extended remedy, in sufferers taking medication which will have elevated toxicity within the presence of hypomagnesemia or medication which will trigger hypomagnesemia. Therapy of hypomagnesemia could require magnesium alternative and discontinuation of VOQUEZNA.
Take into account monitoring magnesium and calcium ranges previous to initiation of VOQUEZNA and periodically whereas on remedy in sufferers with a preexisting danger of hypocalcemia. Complement with magnesium and/or calcium, as obligatory. If hypocalcemia is refractory to remedy, take into account discontinuing VOQUEZNA.
Interactions with Diagnostic Investigations for Neuroendocrine Tumors: Serum chromogranin A (CgA) ranges improve secondary to drug-induced decreases in gastric acidity. The elevated CgA stage could trigger false optimistic ends in diagnostic investigations for neuroendocrine tumors. Briefly discontinue VOQUEZNA remedy no less than 4 weeks earlier than assessing CgA ranges and take into account repeating the check if preliminary CgA ranges are excessive.
Fundic Gland Polyps: Use of VOQUEZNA is related to a danger of fundic gland polyps that will increase with long-term use, particularly past one yr. Fundic gland polyps have been reported with vonoprazan in scientific trials and through postmarketing use with PPIs. Most sufferers who developed fundic gland polyps have been asymptomatic and fundic gland polyps have been recognized by the way on endoscopy. Use the shortest length of VOQUEZNA acceptable to the situation being handled.
ADVERSE REACTIONS:
Therapeutic of Erosive GERD: The most typical antagonistic reactions ( ‰¥2% of sufferers within the VOQUEZNA arm) embody gastritis (3%), diarrhea (2%), stomach distention (2%), stomach ache (2%), and nausea (2%).
Upkeep of Healed Erosive GERD: The most typical antagonistic reactions ( ‰¥3% of sufferers within the VOQUEZNA arm) embody gastritis (6%), stomach ache (4%), dyspepsia (4%), hypertension (3%), and urinary tract an infection (3%).
Reduction of Heartburn Related to Non-Erosive GERD: The most typical antagonistic reactions ( ‰¥2% of sufferers within the VOQUEZNA arm) embody stomach ache (2%), constipation (2%), diarrhea (2%), nausea (2%), and urinary tract an infection (2%).
Therapy of H. Pylori An infection (VOQUEZNA and Amoxicillin): The most typical antagonistic reactions ( ‰¥2% in any remedy arm) embody diarrhea (5%), stomach ache (3%), vulvovaginal candidiasis (2%), nasopharyngitis (2%), dysgeusia (1%), headache (1%), and hypertension (1%).
Therapy of H. Pylori An infection (VOQUEZNA, Amoxicillin and Clarithromycin): The most typical antagonistic reactions ( ‰¥2% in any remedy arm) embody dysgeusia (5%), diarrhea (4%), vulvovaginal candidiasis (3%), headache (3%), stomach ache (2%), hypertension (2%), and nasopharyngitis (<1%).
For extra info on antagonistic reactions and laboratory modifications with amoxicillin or clarithromycin, check with Hostile Reactions part of the corresponding prescribing info.
DRUG INTERACTIONS
VOQUEZNA has the potential for clinically essential drug interactions, together with interactions with medication depending on gastric pH for absorption, medication which might be substrates for sure CYP enzymes, and a few diagnostic checks. Keep away from concomitant use of VOQUEZNA with atazanavir or nelfinavir. See full Prescribing Info for extra particulars about essential drug interactions. Seek the advice of the labeling of concomitantly used medication to acquire additional details about interactions with vonoprazan.
For details about drug interactions, contraindications, and warnings and precautions of antibacterial brokers (amoxicillin or clarithromycin) indicated together with VOQUEZNA, check with their corresponding prescribing info.
USE IN SPECIFIC POPULATIONS
Lactation: Breastfeeding shouldn’t be beneficial throughout remedy. Due to the potential danger of antagonistic liver results proven in animal research with vonoprazan, advise sufferers to not breastfeed throughout remedy with VOQUEZNA.
Renal Impairment: For the therapeutic of Erosive GERD, dosage discount is beneficial in sufferers with extreme renal impairment (eGFR < 30 mL/min). Use of VOQUEZNA shouldn’t be beneficial for the remedy of H. pylori an infection in sufferers with extreme renal impairment.
Hepatic Impairment: For the therapeutic of Erosive GERD, dosage discount is beneficial in sufferers with average to extreme hepatic impairment (Youngster-Pugh Class B and C). Use of VOQUEZNA shouldn’t be beneficial for the remedy of H. pylori an infection in sufferers with average to extreme hepatic impairment.
You’re inspired to report suspected antagonistic reactions by contacting Phathom Prescribed drugs at 1-888-775-PHAT (7428) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Info for VOQUEZNA.
Ahead-Wanting Statements
This press launch comprises forward-looking statements. Phrases equivalent to could, will, ought to, anticipate, plan, anticipate, might, intend, goal, undertaking, contemplates, believes, estimates, predicts, potential or proceed and related expressions, are meant to establish forward-looking statements. Traders are cautioned to not place undue reliance on these forward-looking statements, together with statements in regards to the capability of vonoprazan to alleviate signs of GERD following As Wanted dosing and to suppress nocturnal signs amongst sufferers with Non-Erosive GERD. The inclusion of forward-looking statements shouldn’t be considered a illustration by Phathom that any of its plans will probably be achieved. Precise outcomes could differ from these set forth on this press launch because of the dangers and uncertainties inherent in Phathom’s enterprise, together with, with out limitation: further information associated to vonoprazan to alleviate signs of GERD following As Wanted dosing could also be inconsistent with the info produced as of the date hereof, and additional evaluation of current information and evaluation of recent information could result in conclusions completely different from these established as of the date hereof; the inherent dangers of scientific improvement of vonoprazan; Phathom’s dependence on third events in reference to product manufacturing, analysis and preclinical and scientific testing; regulatory developments in the US and international nations; surprising antagonistic negative effects or insufficient efficacy of vonoprazan which will restrict its improvement, regulatory approval and/or commercialization, or could end in recollects or product legal responsibility claims; Phathom’s capability to acquire and preserve mental property safety and non-patent regulatory exclusivity for vonoprazan; Phathom’s estimates relating to affected person inhabitants and industrial protection might show to be inaccurate; and different dangers described within the Firm’s prior press releases and the Firm’s filings with the Securities and Trade Fee (SEC), together with below the heading Threat Elements within the Firm’s most up-to-date Annual Report on Kind 10-Ok and any subsequent filings with the SEC. You’re cautioned to not place undue reliance on these forward-looking statements, which converse solely as of the date hereof, and Phathom undertakes no obligation to replace such statements to replicate occasions that happen or circumstances that exist after the date hereof. All forward-looking statements are certified of their entirety by this cautionary assertion, which is made below the protected harbor provisions of the Personal Securities Litigation Reform Act of 1995.
References
- VOQUEZNA. Prescribing Info. Phathom Prescribed drugs; 2024.
- Knowledge on file. Phathom Prescribed drugs, Inc. Florham Park, NJ
- Fass R, et al. Heartburn Frequency and Symptom Enchancment Charges of Handled Episodes when Switching From Every day to On-Demand Vonoprazan Therapy for Non-Erosive Reflux Illness; American Faculty of Gastroenterology (ACG) 2024 summary; October 25-30, Philadelphia, PA.
- Fass R, Vaezi M, Sharma P, et al. Randomised scientific trial: Efficacy and security of on-demand vonoprazan versus placebo for non-erosive reflux illness. Accessed September 17, 2024. Accessible at: https://doi.org/10.1111/apt.17728
- Antunes C, Aleem A, Curtis SA. Gastroesophageal reflux illness. NCBI Bookshelf. Accessed January 21, 2024. Accessible at: https://www.ncbi.nlm.nih.gov/books/NBK441938/?report=printable
- Antunes C, et al. Vonoprazan Improves Nocturnal Gastroesophageal Reflux Signs in Non-Erosive Reflux Illness; American Faculty of Gastroenterology (ACG) 2024 summary; October 25-30, Philadelphia, PA.
- Machiacado JD (NASDAQ:), Greer JB, Yadav D. (2021) Epidemiology of Gastrointestinal Ailments. In: Pitchumoni CS, Dharmarajan T, (eds). Geriatric Gastroenterology. Springer, Cham. https://doi.org/10.1007/978-3-030-30192-7_7
- Antunes C, Aleem A, Curtis SA. Gastroesophageal reflux illness. NCBI Bookshelf. Accessed January 21, 2024. Accessible at: https://www.ncbi.nlm.nih.gov/books/NBK441938/?report=printable
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
[email protected]
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
[email protected]
© 2024 Phathom Prescribed drugs. All rights reserved.
VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Prescribed drugs, and their respective logos are registered logos of Phathom Prescribed drugs, Inc.
Supply: Phathom Prescribed drugs
